Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
72
LOBE.CX Quote, Financials, Valuation and Earnings
Last price:
$0.05
Seasonality move
:
27%
Day range:
$0.05 - $0.05
52-week range:
$0.02 - $0.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.72x
Volume:
12.4K
Avg. volume:
41.3K
1-year change:
150%
Market cap:
$13.5M
Revenue:
--
EPS (TTM):
-$0.03
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -- | -- | -- | -- |
|
AGN.CX
Algernon Health, Inc.
|
-- | -- | -- | -- | -- |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LOBE.CX
Lobe Sciences Ltd.
|
$0.05 | -- | $13.5M | -- | $0.00 | 0% | -- |
|
AGN.CX
Algernon Health, Inc.
|
$0.06 | -- | $2.5M | -- | $0.00 | 0% | -- |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0250 | -- | $256.9K | 0.65x | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LOBE.CX
Lobe Sciences Ltd.
|
40.99% | -3.893 | 19.05% | 2.85x |
|
AGN.CX
Algernon Health, Inc.
|
-- | -0.465 | -- | 0.03x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 4.663 | 20.53% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -$1.1M | -1117.27% | -- | -- | -$408.2K |
|
AGN.CX
Algernon Health, Inc.
|
-$8.7K | -$583.2K | -96.85% | -96.85% | -- | -$174.5K |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
Lobe Sciences Ltd. vs. Competitors
-
Which has Higher Returns LOBE.CX or AGN.CX?
Algernon Health, Inc. has a net margin of -- compared to Lobe Sciences Ltd.'s net margin of --. Lobe Sciences Ltd.'s return on equity of -- beat Algernon Health, Inc.'s return on equity of -96.85%.
Company Gross Margin Earnings Per Share Invested Capital LOBE.CXLobe Sciences Ltd.-- -$0.01 $5.9M AGN.CXAlgernon Health, Inc.-- -$0.02 $1.7M -
What do Analysts Say About LOBE.CX or AGN.CX?
Lobe Sciences Ltd. has a consensus price target of --, signalling upside risk potential of 14192.33%. On the other hand Algernon Health, Inc. has an analysts' consensus of -- which suggests that it could grow by 4559.09%. Given that Lobe Sciences Ltd. has higher upside potential than Algernon Health, Inc., analysts believe Lobe Sciences Ltd. is more attractive than Algernon Health, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LOBE.CXLobe Sciences Ltd.0 0 0 AGN.CXAlgernon Health, Inc.0 0 0 -
Is LOBE.CX or AGN.CX More Risky?
Lobe Sciences Ltd. has a beta of 0.208, which suggesting that the stock is 79.155% less volatile than S&P 500. In comparison Algernon Health, Inc. has a beta of 1.331, suggesting its more volatile than the S&P 500 by 33.05%.
-
Which is a Better Dividend Stock LOBE.CX or AGN.CX?
Lobe Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Algernon Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lobe Sciences Ltd. pays -- of its earnings as a dividend. Algernon Health, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LOBE.CX or AGN.CX?
Lobe Sciences Ltd. quarterly revenues are --, which are smaller than Algernon Health, Inc. quarterly revenues of --. Lobe Sciences Ltd.'s net income of -$1.1M is lower than Algernon Health, Inc.'s net income of -$583.2K. Notably, Lobe Sciences Ltd.'s price-to-earnings ratio is -- while Algernon Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lobe Sciences Ltd. is -- versus -- for Algernon Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LOBE.CXLobe Sciences Ltd.-- -- -- -$1.1M AGN.CXAlgernon Health, Inc.-- -- -- -$583.2K
-
Which has Higher Returns LOBE.CX or COOL.CX?
Core One Labs, Inc. has a net margin of -- compared to Lobe Sciences Ltd.'s net margin of --. Lobe Sciences Ltd.'s return on equity of -- beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LOBE.CXLobe Sciences Ltd.-- -$0.01 $5.9M COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About LOBE.CX or COOL.CX?
Lobe Sciences Ltd. has a consensus price target of --, signalling upside risk potential of 14192.33%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Lobe Sciences Ltd. has higher upside potential than Core One Labs, Inc., analysts believe Lobe Sciences Ltd. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LOBE.CXLobe Sciences Ltd.0 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is LOBE.CX or COOL.CX More Risky?
Lobe Sciences Ltd. has a beta of 0.208, which suggesting that the stock is 79.155% less volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock LOBE.CX or COOL.CX?
Lobe Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lobe Sciences Ltd. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LOBE.CX or COOL.CX?
Lobe Sciences Ltd. quarterly revenues are --, which are larger than Core One Labs, Inc. quarterly revenues of --. Lobe Sciences Ltd.'s net income of -$1.1M is higher than Core One Labs, Inc.'s net income of --. Notably, Lobe Sciences Ltd.'s price-to-earnings ratio is -- while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lobe Sciences Ltd. is -- versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LOBE.CXLobe Sciences Ltd.-- -- -- -$1.1M COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns LOBE.CX or CURE.X.CX?
Biocure Technology has a net margin of -- compared to Lobe Sciences Ltd.'s net margin of --. Lobe Sciences Ltd.'s return on equity of -- beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LOBE.CXLobe Sciences Ltd.-- -$0.01 $5.9M CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About LOBE.CX or CURE.X.CX?
Lobe Sciences Ltd. has a consensus price target of --, signalling upside risk potential of 14192.33%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Lobe Sciences Ltd. has higher upside potential than Biocure Technology, analysts believe Lobe Sciences Ltd. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings LOBE.CXLobe Sciences Ltd.0 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is LOBE.CX or CURE.X.CX More Risky?
Lobe Sciences Ltd. has a beta of 0.208, which suggesting that the stock is 79.155% less volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LOBE.CX or CURE.X.CX?
Lobe Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lobe Sciences Ltd. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LOBE.CX or CURE.X.CX?
Lobe Sciences Ltd. quarterly revenues are --, which are larger than Biocure Technology quarterly revenues of --. Lobe Sciences Ltd.'s net income of -$1.1M is higher than Biocure Technology's net income of --. Notably, Lobe Sciences Ltd.'s price-to-earnings ratio is -- while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lobe Sciences Ltd. is -- versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LOBE.CXLobe Sciences Ltd.-- -- -- -$1.1M CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns LOBE.CX or HEAL.CX?
has a net margin of -- compared to Lobe Sciences Ltd.'s net margin of --. Lobe Sciences Ltd.'s return on equity of -- beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LOBE.CXLobe Sciences Ltd.-- -$0.01 $5.9M HEAL.CX-- -- -- -
What do Analysts Say About LOBE.CX or HEAL.CX?
Lobe Sciences Ltd. has a consensus price target of --, signalling upside risk potential of 14192.33%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Lobe Sciences Ltd. has higher upside potential than , analysts believe Lobe Sciences Ltd. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings LOBE.CXLobe Sciences Ltd.0 0 0 HEAL.CX0 0 0 -
Is LOBE.CX or HEAL.CX More Risky?
Lobe Sciences Ltd. has a beta of 0.208, which suggesting that the stock is 79.155% less volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LOBE.CX or HEAL.CX?
Lobe Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lobe Sciences Ltd. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LOBE.CX or HEAL.CX?
Lobe Sciences Ltd. quarterly revenues are --, which are larger than quarterly revenues of --. Lobe Sciences Ltd.'s net income of -$1.1M is higher than 's net income of --. Notably, Lobe Sciences Ltd.'s price-to-earnings ratio is -- while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lobe Sciences Ltd. is -- versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LOBE.CXLobe Sciences Ltd.-- -- -- -$1.1M HEAL.CX-- -- -- --
-
Which has Higher Returns LOBE.CX or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of -- compared to Lobe Sciences Ltd.'s net margin of --. Lobe Sciences Ltd.'s return on equity of -- beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LOBE.CXLobe Sciences Ltd.-- -$0.01 $5.9M NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About LOBE.CX or NSHS.CX?
Lobe Sciences Ltd. has a consensus price target of --, signalling upside risk potential of 14192.33%. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Lobe Sciences Ltd. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe Lobe Sciences Ltd. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LOBE.CXLobe Sciences Ltd.0 0 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is LOBE.CX or NSHS.CX More Risky?
Lobe Sciences Ltd. has a beta of 0.208, which suggesting that the stock is 79.155% less volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.631, suggesting its less volatile than the S&P 500 by 36.894%.
-
Which is a Better Dividend Stock LOBE.CX or NSHS.CX?
Lobe Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lobe Sciences Ltd. pays -- of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LOBE.CX or NSHS.CX?
Lobe Sciences Ltd. quarterly revenues are --, which are smaller than NanoSphere Health Sciences, Inc. quarterly revenues of --. Lobe Sciences Ltd.'s net income of -$1.1M is lower than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, Lobe Sciences Ltd.'s price-to-earnings ratio is -- while NanoSphere Health Sciences, Inc.'s PE ratio is 0.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lobe Sciences Ltd. is -- versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LOBE.CXLobe Sciences Ltd.-- -- -- -$1.1M NSHS.CXNanoSphere Health Sciences, Inc.-- 0.65x -- -$13.1K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
69
RGC alert for Jan 7
Regencell Bioscience Holdings Ltd. [RGC] is up 58.95% over the past day.
Buy
69
WDC alert for Jan 7
Western Digital Corp. [WDC] is down 8.88% over the past day.
Buy
75
DRUG alert for Jan 7
Bright Minds Biosciences, Inc. [DRUG] is up 2.99% over the past day.
